Abstract The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ 9 -tetrahydrocannabinol (but not for most other plant cannabinoids or phytocannabinoids)-cannabinoid receptor type-1 (CB 1 R) and cannabinoid receptor type-2 (CB 2 R); their two most studied endogenous ligands, the "endocannabinoids" N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and the enzymes responsible for endocannabinoid metabolism. However, anandamide and 2-AG, and also the phytocannabinoids, have more molecular targets than just CB 1 R and CB 2 R. Furthermore, the endocannabinoids, like most other lipid mediators, have more than just one set of biosynthetic and degrading pathways and enzymes, which they often share with "endocannabinoid-like" mediators that may or may not interact with the same proteins as Δ 9 -tetrahydrocannabinol and other phytocannabinoids. In some cases, these degrading pathways and enzymes lead to molecules that are not inactive and instead interact with other receptors. Finally, some of the metabolic enzymes may also participate in the chemical modification of molecules that have very little to do with endocannabinoid and cannabinoid targets. Here, we review the whole world of ligands, receptors, and enzymes, a true "endocannabinoidome", discovered after the cloning of CB 1 R and CB 2 R and the identification of anandamide and 2-AG, and its interactions with phytocannabinoids.
Introduction
Giving a definition of the complex endogenous signaling system known as the "endocannabinoid system" is becoming an increasingly difficult task. In fact, the number of potential components of this system, which was originally identified from studies on the mechanism of action of the psychotropic ingredient of some varieties of cannabis, Δ 9 -tetrahydrocannabinol (THC), is increasing with the passing years, and the definition of "endocannabinoid" is also bound to change in the near future [1] .
At the turn of the century, the endocannabinoid system was defined as the ensemble of 1) two 7-transmembrane-domain and G protein-coupled receptors (GPCRs) for THC-cannabinoid receptor type-1 (CB 1 R) and cannabinoid receptor type-2 (CB 2 R); 2) their 2 most studied endogenous ligands, the "endocannabinoids" N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and 3) the 5 enzymes believed, at that time, to be uniquely responsible for endocannabinoid biosynthesis [i.e., N-acyl-phosphatidyl-ethanolamine-selective phospholipase D (NAPE-PLD) and diacylglycerol lipases (DAGL) α and β, for anandamide and 2-AG, respectively] and hydrolytic inactivation [i.e., fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), for anandamide and 2-AG, respectively] ( Fig. 1 ) [2] . This definition, however, presented a few semantic problems [1] : 1) of the > 80 cannabinoids naturally found in cannabis (with different relative composition depending on the cannabis variety), only THC and its less abundant propyl Electronic supplementary material The online version of this article (doi:10.1007/s13311-015-0374-6) contains supplementary material, which is available to authorized users. Fig. 1 Complexity, redundancy, and promiscuity of the endocannabinoid system: the "endocannabinodome" and the interactions therewith of plant cannabinoids. Several often concurrent pathways underlie both the biosynthesis and the inactivation of the 2 most studied endocannabinoids, anandamide, and 2-arachidonoylglycerol (2-AG). Anandamide biosynthetic precursors, the N-arachidonoyl-phosphatidylethanolamines, are produced from the remodeling of phospholipids via the action of Nacyl-transferases (NATs). They are then converted to anandamide, either in 1 step, by N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD), or in sequential steps, i.e. by α,β -hydrolase-4 (ABHD4) followed by phosphodiesterase GDE1; or soluble phospholipase A2 (sPLA2) followed by lysophospholipase D (lyso-PLD); or by phospholipase C (PLC) enzymes followed by phosphatases such as PTPN22. The sn-2-arachidonate-containing diacylglycerols serving as biosynthetic precursors for 2-AG are in most cases produced from the action of PLCβ but can also come from phosphatidic acid (PA) via PA phosphohydrolase. However, 2-AG can be also produced from sn-1-lysophospholipids via the sequential action of phospholipase A1 (PLA1) and lyso-phospholipase C, or (not shown here) from the dephosphorylation of lysophosphatidic acid. These biosynthetic pathways are shared by anandamide and 2-AG with other N-acyl-ethanolamines and 2-monoacyl-glycerols, respectively. These congeners, in most cases, do not activate directly the 2 cannabinoid receptors (denoted as CB 1 and CB 2 here, and as CB 1 R and CB 2 R in the main text), but have other targets, some of which shown here, such as orphan G-protein-coupled receptors (GPR55, GPR18, GPR119); the transient receptor potential of vanilloidtype 1 (TRPV1) channel; and peroxisome proliferator-activated nuclear receptors (PPARs). However, also anandamide and, to a lesser extent, 2-AG, have been suggested to be capable of activating some of these targets, particularly TRPV1 and GPR55. Anandamide also inhibits the transient receptor potential melastatin type-8 (TRPM8) channel (blue broken arrow). Both anandamide and 2-AG, following their cellular reuptake by cells, which might be facilitated by a yet-to-be-characterized endocannabinoid membrane transporter (EMT), are inactivated inside cells by enzymatic hydrolysis, respectively by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In some cells FAAH, α,β-hydrolase-6 (ABHD6) and, even less frequently, α,β-hydrolase-12 (ABHD12), can also hydrolyze 2-AG. These enzymes are also responsible for the enzymatic hydrolysys of other N-acyl-ethanolamines and 2-mono-acyl-glycerols, respectively, although N-palmitoylethanolamine is preferentially hydrolyzed by N-acyl-ethanolamine acid amidohydrolase (not shown). The 2 endocannabinoids, but not their nonpolyunsaturated congeners, can also be oxidized by cyclooxygenase-2 (COX-2), and then processed by prostaglandin synthases, to produce prostamides, in the case of anandamide, and prostaglandin-glycerol esters, in the case of 2-AG. This latter endocannabinoid, via the action of MAGL or ABHD6, can also act as biosynthetic precursor for the nonphospholipase A2-mediated production of prostanoids. Apart from Δ 9 -tetrahydrocannabinol (THC), plant cannabinoids mentioned in the main text, such as cannabidiol (CBD), CBD acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), Δ 9 -tetrahydrocannabivarin (THCV), THCV acid (THCVA), and CBDV acid (CBDVA), either activate (red solid arrows) or inhibit (red broken arrows) some of the receptors and enzymes of the "endocannabinoidome". However, they often do so at medium-high micromolar concentrations, and the weight of such interactions in their pharmacology, as compared with others that they have also been suggested to exert, has not yet been fully assessed. Abn-CBD = abnormal cannabidiol; DAG = diacylglycerol; PLCβ = phospholipase β. Adapted from Di Marzo [58] analogue, Δ 9 -tetrahydrocannabivarin (THCV), are capable of binding with high affinity to CB 1 R and CB 2 R (with agonist and antagonist activity for THC and THCV, respectively); hence, these 2 receptors should not be defined as "cannabinoid" receptors, but rather as THC/THCV receptors [alternatively the definition of "cannabinoid receptor" should also include those proteins that often bind to cannabinoids, such as the thermosensitive transient receptor potential (TRP) cation channels (thermo-TRPs) [3] (see below)]; 2) as a consequence, "endocannabinoids" should not be the endogenous ligands of CB 1 R and CB 2 R, but rather the ligands of all those "cannabinoid receptors" that uniquely and selectively bind to cannabinoids in general (thus, anandamide and 2-AG might not be the only endocannabinoids); and 3) again, as a consequence, "endocannabinoid enzymes" would not only be NAPE-PLD, the two DAGLs, FAAH, and MAGL, but also other enzymes responsible for the biosynthesis and inactivation of the other mediators to be eventually included in the list of the endocannabinoids.
Although that depicted above would seem like the natural "evolution" of the definition of the "endocannabinoid system", things are likely to be even more complicated. First, endocannabinoids, and also cannabinoids, have more molecular targets than just CB 1 R, CB 2 R, or thermo-TRPs, and these receptors appear to extend also to proteins that are targeted by other endogenous and exogenous substances. Furthermore, anandamide and 2-AG, like most other lipid mediators, have more than just 1 set of biosynthetic and degrading pathways and enzymes each (Fig. 1) , which they often share with "endocannabinoid-like" mediators that may or may not be part of the extended definition of "endocannabinoids" provided above, that is, they may or may not interact with the same proteins to which non-THC cannabinoids bind. In some cases, these degrading pathways and enzymes lead to molecules, such as the prostamides and prostaglandin-glycerol esters ( Fig. 1) , which are not inactive but instead interact with other receptors, that is, these enzymes are "degrading" for endocannabinoids and "biosynthetic" for other mediators. Finally, some of these enzymes may also have additional completely different functions, for example participate in the chemical modification of molecules that have very little to do with endocannabinoid and cannabinoid targets.
As a result of the above reasoning, some authors now use an extended definition of the endocannabinoid system, such the "enlarged endocannabinoid system". We, instead, for the s a k e o f c l a r i t y, p r e f e r t o us e t h e de f i ni t i o n of "endocannabinoid-like" mediators [1] , that is, mediators belonging to the same chemical class as the endocannabinoids (i.e., amides or esters of long-chain fatty acids), which are not necessarily linked metabolically to anandamide and 2-AG, and have as preferential receptors proteins different from CB 1 R and CB 2 R. The ensemble of endocannabinoids, endocannabinoid-like mediators, and their several receptors and metabolic enzymes could then be defined as the "endocannabinoidome" [4] . This is not because its function is necessarily overlapping with that of CB 1 R and CB 2 R, but because the genetic or pharmacological manipulation of one member of this new "ome" may ricochet on the activity of these 2 receptors by indirectly influencing the levels or action of anandamide and 2-AG (Fig. 1) ; hence, the necessity of studying the impact of such manipulations on this system as a whole, by employing the typical methodologies (genomics, transcriptomics, kinomics, metabolomics, lipidomics, etc.) used to investigate the expression and activity of several genes, proteins, and metabolites at once.
Endocannabinoids, Plant cannabinoids and Thermo-TRPs
The first evidence that anandamide and capsaicin, that is, the prototypical plant-derived activator of heat-sensitive TRP channels of vanilloid type-1 (TRPV1), and pungent component of capsicum, have something in common came when some synthetic TRPV1 agonists were found to inhibit the cellular reuptake of anandamide [5] . Immediately thereafter, anandamide was shown to be the first endogenous agonist of both human and rat TRPV1 channels [6] , although it was soon clear that this endocannabinoid was not the only lipid mediator capable of exerting this function [7] . Anandamide was later found also to antagonize TRP channels of melastatin type-8 (TRPM8), which are instead activated by low temperatures and menthol [8] , whereas the other cold-activated TRP, the TRP channel of ankyrin type-1 (TRPA1), activated by mustard oils, was sensitive only to high micromolar concentrations of the endocannabinoid. The stimulatory, and subsequently desensitizing, effects of anandamide at TRPV1 have been reported in hundreds of studies and represent one of the most important mechanisms, after CB1 activation, through which this lipid mediator exerts its biological functions [9] . Recently, 2-AG was also shown to activate TRPV1, although at concentrations higher than those required to anandamide to produce the same effect [10, 11] .
Importantly, both THC and non-THC cannabinoids can interact with thermo-TRPs, often in a manner similar to anandamide. The other most abundant, and nonpsychotropic, cannabinoid, cannabidiol (CBD) and, less potently, THCV, cannabigerol (CBG), cannabigerovarin (CBGV), and cannabidivarin (CBDV), activate and desensitize human TRPV1, whereas CBD, CBDV, THCV, and CBG, as well as THC, antagonize rat TRPM8. All these compounds, as well as cannabichromene activate and desensitize rat TRPA1 [12, 13] . Of these effects, only TRPM8 antagonism is also exerted by cannabinoids in their acid form (which is also the form in which they are naturally produced by the plant) [13] . Of other proposed heat-sensitive TRP channels, that is TRPV2, TRPV3, and TRPV4, only CBD, CBG, CBGV, THC, and, less potently, THCV, activate and desensitize TRPV2 [13] , whereas only CBD and THCV are capable of activating and desensitizing rat TRPV3, which is potently desensitized, but not potently activated, by CBGV [14] . Finally, only THCV is a reasonably good activator of the rat TRPV4, although CBD and CBGV potently desensitize this channel [14] .
It is important to emphasize that only a few of these effects, which were observed using calcium imaging techniques in intact cells, have been so far confirmed to be due to direct interactions with the channels by using, for example, patch clamp electrophysiology. In particular, this is true to date only for CBD and CBDV activation of TRPV1, TRPV2, and TRPA1 [15, 16] . Unpublished electrophysiological evidence also exists for the antagonism of TRPM8 (Thomas Voets, personal communication). Nevertheless, the abovementioned thermo-TRPs, especially in the absence of other strong and specific exogenous/xenobiotic modulators, are now considered by all means bona fide "ionotropic cannabinoid receptors", whereas CB 1 R and CB 2 R would thus be defined as "metabotropic cannabinoid receptors" [3, 17, 18] . Importantly, several "endocannabinoid-like" mediators, such as, on the one hand, the anandamide congeners N-palmitoylethanolamine, N-oleoylethanolamine, and N-linoleoylethanolamine, as well as several N-acyl-dopamines and N-acyl-taurines, as direct or indirect activators [11, [19] [20] [21] [22] , and, on the other hand, some N-acyl-serotonins, as competitive antagonists [23, 24] , have been shown to interact with TRPV1 in in vitro and in vivo studies.
Other Ways Through Which non-THC Plant Cannabinoids Influence the Endocannabinoid System
Apart from activating (in the case of THC) or antagonizing (in the case of THCV) CB 1 R and CB 2 R [25] , plant cannabinoids have other ways of potentially and indirectly modifying the activity of the endocannabinoid system. Most nonacid plant cannabinoids inhibit, albeit not very potently, the cellular reuptake of anandamide, and CBD is also a moderate inhibitor of anandamide hydrolysis by FAAH [13, 26] , an effect that has been recently reported to also occur in vivo in mice and humans [27, 28] . If one remembers that several endocannabinoid-like mediators are also inactivated by FAAH (Fig. 1) , a consequence of the above findings is that plant cannabinoids can affect the tissue levels of these compounds, too.
None of the cannabinoids tested thus far exerts potent inhibition of 2-AG inactivation by MAGL, although botanical extracts from cannabis varieties producing preferentially either CBG, CBG acid or, particularly, THC acid, as opposed to the pure compounds, do inhibit this enzyme at concentrations<50 μM, suggesting the presence of MAGL inhibitors among the noncannabinoid components of the extracts [13] . Conversely, pure CBDV, CBG acid, CBD acid, THC acid, and CBDV acid weakly inhibit (with IC 50 values in the 16.6-27.3 μM range) 2-AG biosynthesis by DAGLα [13] . There are also indirect ways through which CBD (which has extremely low affinity for CB 1 R and CB 2 R) inhibits CB1 activity, particularly in the central nervous system, and these have been recently reviewed by McPartland et al. [29] .
Finally, at high concentrations, THCV behaves as a CB2 agonist, as shown by in vitro and in vivo studies [25, 30, 31] .
How do Endocannabinoid-like Mediators Influence the Activity of CB 1 R and CB 2 R?
Most endocannabinoid-like mediators, that is, those compounds that, according to the definition given above, are not part of the endocannabinoid system but contribute to constitute the endocannabinoidome, do not directly influence the activity of CB 1 R and CB 2 R. Whilst some controversial data exist as to the capability of nonarachidonate-containing, polyunsaturated N-acyl-ethanolamines [32, 33] , as well as of the primary amide of oleic acid and sleep-inducing factor, oleamide [34] , to activate these receptors functionally, some endogenously occurring amides and esters of long chain fatty acids can influence CB1 and CB2 action only indirectly. Npalmitoyl-ethanolamide and, particularly, N-oleoyl-and Nlinoleoyl-ethanolamide, by acting as alternative substrates for FAAH [35] , can retard the degradation of anandamide, and the same is true for some unsaturated N-acyl-amino acids, particularly N-arachidonoyl-glycine [36, 37] , and N-acyl-taurines [38] . Furthermore, N-palmitoyl-ethanolamide can reduce the expression of FAAH after prolonged exposure of human breast cancer cells [39] . Likewise, the mono-acyl-glycerols of palmitic, oleic, and linoleic acids enhance the functional activity of 2-AG at CB 1 R and CB 2 R, seemingly by inhibiting 2-AG enzymatic hydrolysis [40] .
Conclusions: The Overlap Between the "Endocannabinoidome" and the "Phytocannabinoidome"
From the evidence reviewed in this article, it is clear that the "endocannabinoidome" and the ensemble of the plant cannabinoids and their molecular targets, which could be defined by analogy as the "phytocannabinoidome", overlap to some extent. The commonalities between these 2 "omes" are even more striking if one looks at alternative targets (i.e., other than CB receptors and thermo-TRP channels) that have been proposed to date for endocannabinoid-like mediators and phytocannabinoids (see [41] for review). When such targets are receptors, they belong to all 3 major receptor classes, i.e. GPCRs, ligand-sensitive ion channels, and nuclear receptors. In particular: 1) the orphan GPCR, GPR55, has been suggested to act as target for both cannabinoids, that is, THC and CBD, which seem to act as agonist and antagonist, respectively, for this receptor [42] , and N-palmitoylethanolamine, which seems to be an agonist [42] . In fact, there is controversial evidence that anandamide and 2-AG may also activate GPR55, and the recent finding of CB1-GPR55 heteromers might explain why some authors have found that the 2 endocannabinoids directly activate this orphan GPCR and most others have not [43] [44] [45] [46] . Another orphan GPCR, GPR18, is instead activated by N-arachidonoyl-glycine and by a synthetic CBD analogue known as abnormal-cannabidiol [47, 48] . 2) Ttype Ca 2+ channels have been suggested to be inhibited by both unsaturated long chain fatty acid amides, including some N--acylethanolamines, N-acyl-serotonins, and N-acyldopamines [49] , and THC and CBD [50] . 3) peroxisome-proliferator activated receptor-α is activated by both anandamide congeners such as N-palmitoylethanolamine and N-oleoylethanolamine [51] , which have in this nuclear receptor their preferred target, and some plant and synthetic cannabinoids [52] ; instead, PPARγ is activated, at concentrations of 1-10 μM, by both CBD and anandamide or 2-AG [53, 54] .
However, endocannabinoid-like mediators have additional targets, which they do not share with phytocannabinoids, and the same is true for the latter compounds. Therefore, the overlap between the "endocannabinoidome" and the "phytocannabinoidome" is only partial. Further interactions can be predicted on the basis of the capability of both polyunsaturated endocannabinoid-like mediators and plant cannabinoids to inhibit, or to be oxidized by, cytochrome p450 oxygenases [55, 56] , which, in theory, allows the latter compounds, when administered systemically, to modulate the levels of the former. Finally, CBD acid, and much less so THC acid, were reported to inhibit cycloxygenase-2 [57] , thus potentially inhibiting the formation not only of prostanoids, but also of prostamides and prostaglandin-glycerol esters. However, such interactions are yet to be demonstrated in vivo. Likewise, most of the interactions between these endogenous and xenobiotic compounds and the targets mentioned in this section have been shown to occur in vitro and their relevance to in vivo pharmacology is yet to be fully clarified. It is, in fact, also the realization that much work still needs to be done to dissect the pharmacological importance of the "endocannabinoidome" and the "phytocannabinoidome", and, hence, to evaluate fully their and biological/therapeutic relevance, that has convinced many scientists working on this topic to focus so far mostly on the "endocannabinoid system" as it was defined at the turn of the century.
The role of this system and the capability of the most abundant plant cannabinoids, namely THC and CBD, to modulate it in the framework of the treatment of neurological and neuropsychiatric disorders, is the theme of this special issue and of the following chapters.
